<DOC>
	<DOC>NCT00694356</DOC>
	<brief_summary>A clinical study evaluates the safety, tolerability, pharmacokinetics, and immunogenicity of MK0646 in patients with relapsed or refractory locally advanced or metastatic solid tumors using a once weekly and an every other week dose infusion regimen.</brief_summary>
	<brief_title>Study of MK0646 in Patients With Solid Tumors (0646-009)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically Or Cytologically Confirmed Metastatic Or Locally Advanced Solid Tumors That Has Failed To Respond To Standard Therapy, Or For Which Adequate Standard Therapy Dose Not Exist Tumors Associated With Igf1r Expression In The Literature (E.G. Prostate, Pancreatic, Colon, Lung And Breast) Ecog Performance Status 0 or 1 Adequate Organ Function Patient Who Has Had Chemotherapy, Radiotherapy, Or Biological Therapy Within 4 Weeks (6 Weeks For Nitrosoureas Or Mitomycin C) Prior To Registration Patients Is Concurrently Using Growth Hormone (Gh), Or Growth Hormone Inhibitor Any Active CNS Metastases And/Or Carcinomatous Meningitis Any Primary Central Nervous System Tumor Any Symptomatic Ascites Or Plural Effusion A History Or Current Evidence Of Any Clinically Significant Disease That Might Confound The Results Of The Study, Complicate The Interpretation Of The Study Results, Interfere With The Patient'S Participation, Or Pose An Additional Risk To The Patient Pregnant Or BreastFeeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>